#Biotech

CAR T cell therapy, proven in blood cancers, is now in hundreds of clinical trials for MS, lupus, and other autoimmune conditions. What the science shows—and what it doesn't yet.

R3 Bio wants to grow human bodies without brains as biological backups. The science is speculative. The ethics are explosive. And the legal framework doesn't exist yet.

Colossal Biosciences raised hundreds of millions to resurrect woolly mammoths and dire wolves. What they're actually doing is more complicated—and more interesting.

California startup R3 Bio quietly pitched investors on 'brainless human clones' as backup bodies—beyond its public story of nonsentient organ sacks for drug testing. A deep dive into biotech's most ethically charged frontier.

Insilico Medicine's $2.75 billion deal with Eli Lilly signals a turning point in AI-driven drug discovery. Here's what it means for biotech investors and the pharma industry.

Semaglutide's patent expired in China on March 20. Now at least 10 Chinese rivals are queuing for approval, some claiming better efficacy. A $14B market is up for grabs.

From cryonics to de-extinction, biotechnology is redrawing the line between life and death. What does that mean for how we live, grieve, and understand ourselves?

Samsung Biologics and Eli Lilly will co-establish a Lilly Gateway Labs site in Songdo, Incheon by 2027. What does this mean for Korea's biotech ecosystem and global pharma strategy?

Max Hodak's Science Corp raises $230M for rice-grain sized chip that restores vision to blind patients. Could beat Neuralink as first BCI company to commercialize

Barclays dramatically cuts Novo Nordisk's CagriSema revenue projections from $25.4B to $4.4B, sending shockwaves through pharma investment community and raising questions about obesity drug market reality.

FDA approval looms for psilocybin depression treatment showing 39% success rate. But are we ready to embrace psychedelics as medicine?

Trump appointee overruled FDA scientists to reject Moderna's mRNA flu vaccine, then reversed course within a week after public backlash. Political interference in vaccine approval raises concerns.